References
1. Code of Federal Regulations, Title 21, Food and Drugs (Government Printing Office, Washington, DC), Chapter I, Part 3, Subchapter A, Sec. 3.2 (e).
2. FDA, FY 2011 Performance Report to Congress for the Office of Combination Products (Rockville, MD).
3. FDA, "Frequently Asked Questions About Combination Products" (Rockville, MD),
http://www.fda.gov/CombinationProducts/AboutCombinationProducts/ucm101496.htm, accessed Sept. 15, 2012.
4. Code of Federal Regulations, Title 21, Food and Drugs (Government Printing Office, Washington, DC) Chapter 1, Part 300, Subpart B, Sec. 300.50.
5. FDA, FDA Approved Drugs, Drugs@FDA, accessed Sept. 15, 2012.
6. A. Kane, D. Monterroza, and C. Salazar, "Unlocking the Power of New Softgel Technology for Multiple Formulations" Webcast,
Pharm. Technol.,
http://www.PharmTech.com/apiformulations/, accessed Sept. 15, 2012.
7. FDA, Label for Janumet XR (Rockville, MD, 2012).
8. FDA, Label for Juvisync (Rockville, MD, 2011).
9. FDA, Label for Qsymia (Rockville, MD, 2012).
10. FDA, Label for Jalyn (Rockville, MD, 2010).
11. FDA,Label for Suboxone Sublingual Film (Rockville, MD, 2010).
|
